Onconetix (NASDAQ:ONCO) Posts Earnings Results, Beats Expectations By $44,973.99 EPS

Onconetix (NASDAQ:ONCO – Get Free Report) released its quarterly earnings data on Monday. The company reported ($76.01) earnings per share for the quarter, beating the consensus estimate of ($45,050.00) by $44,973.99, FiscalAI reports. The firm had revenue of $0.10 million during the quarter, compared to analysts’ expectations of $0.02 million. Onconetix had a negative net margin of 1,575.89% and a negative return on equity of 91.95%.

Onconetix Stock Up 1.7%

ONCO stock opened at $2.96 on Tuesday. Onconetix has a 52 week low of $2.76 and a 52 week high of $1,610.00. The company has a fifty day simple moving average of $6.09 and a two-hundred day simple moving average of $106.54. The firm has a market capitalization of $1.74 million, a P/E ratio of 0.00 and a beta of 2.62.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on ONCO. Weiss Ratings raised shares of Onconetix from a “sell (e)” rating to a “sell (e+)” rating in a research report on Thursday, October 29th. Wall Street Zen raised Onconetix from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat, the company has an average rating of “Sell”.

View Our Latest Analysis on ONCO

Onconetix Company Profile

(Get Free Report)

Onconetix, Inc. is a biotechnology company focused on cancer-related diagnostics and therapeutics, with an emphasis on prostate health. Its portfolio includes Proclarix, a blood-based diagnostic test developed to help assess prostate cancer risk. Proclarix was developed by Swiss company Proteomedix, which Onconetix acquired in 2023. The test has received a CE mark for use in Europe; its availability and regulatory status may differ in other markets. Onconetix was formerly known as Blue Water Biotech before adopting its current name in 2024.

Recommended Stories

Earnings History for Onconetix (NASDAQ:ONCO)

Receive News & Ratings for Onconetix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconetix and related companies with MarketBeat.com's FREE daily email newsletter.